SYBX - Rare Disease Focused-Synlogic Pulls Plug On Lead Program Shares Nosedive | Benzinga
Thursday, Synlogic Inc (NASDAQ:SYBX) announced its decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment for phenylketonuria (PKU).
The company expected data review from the Synpheny-3 study in PKU in the first half of 2024, with the potential to expand the study population to patients aged 12-17. Topline data from the Phase 3 study in PKU was expected in the first half of 2025.
Phenylketonuria is a rare inherited disorder that causes an amino acid called phenylalanine to build up in the body. Untreated ...